There is a period after an injury in which almost nothing appears to be happening and almost everything is being decided. It runs roughly from the end of the first week to the end of the third month, and it is the interval during which most people are told to rest, given a prescription, and asked to come back if it does not settle.
It is also the only interval in the whole course that cannot be recovered later.
What the tissue is doing while nothing appears to happen
Through weeks two to six, fibroblasts lay down type III collagen. It goes down quickly, in no particular orientation, and it is weaker than the type I collagen meant to succeed it. Crucially, it is laid down in whatever shape the limb is held in and under whatever loads it is asked to carry.
From week six onward that provisional matrix is progressively replaced and the fibers align to the direction of load. If there is no load, there is no direction. The tissue consolidates in the configuration of a guarded, protected limb, and the eventual ceiling is set lower than it needed to be. This is not reversible with a later injection, and it is the single strongest argument against the advice to wait and see.
What the window is not for: the injection
In the first days the tissue is already doing the thing a catalyst is meant to provoke. The hematoma at the injury site is itself a platelet delivery; growth factor release is at the top of its range; neutrophils are clearing damaged material and macrophages are queued behind them. The signal is being broadcast at full volume by the body that owns the injury.
Adding a concentrate of that same signal does not raise the volume of anything, because nothing has stopped yet. A catalyst is a tool for a process that has stalled, and stalling is a later event with its own biology — described in why some injuries never finish healing.
The practical consequence is that pressure to inject early is almost always pressure to spend a catalyst at the one moment it cannot do anything, and to spend it instead of doing the three things below, which can.
What the window is for: three things, run in parallel
Establishing what was actually injured
Not what the emergency department excluded — what was injured. Mechanism, examination, and where the pain generator is ambiguous, a diagnostic step that tests the leading candidate rather than another image of the same region. A repair project cannot be managed if the structure under repair has not been named.
Correcting the terrain while there is still time for it to matter
This is the part unique to how we practice, and it is the reason twelve weeks is treated as working time rather than waiting time. Hemoglobin A1c reflects roughly a quarter of glycemic history, so a quarter is the natural unit for moving it. Vitamin D repletion takes weeks. Sleep architecture responds within weeks. Nicotine cessation acts on vasoconstriction almost immediately and on collagen cross-linking over months.
The point of doing this now rather than later is arithmetic. Correcting an inflammatory state in month nine improves the environment for whatever repair is left. Correcting it in month one improves the environment for the repair that is actually happening. The panel is in The Metabolic Audit and the mechanism in Metainflammation.
Loading the tissue on purpose
Graded, progressive, and continued past the point where it stops hurting. This is the mechanical signal that tells remodeling collagen which way to point, and there is no substitute for it — not a brace, not rest, and not an injection. It is argued in full in why load is the treatment.
Anti-inflammatory medication: what is established and what is folklore
A confident claim circulates that anti-inflammatories block healing and must be stopped after any injury. It deserves a careful answer rather than agreement, because the certainty of the claim runs well ahead of the clinical evidence for it.
The largest clinical synthesis available pooled four studies and 4,451 surgical patients, the overwhelming majority of them cruciate ligament reconstructions. Reoperation rates after meniscal repair, cruciate reconstruction and Bankart repair were statistically indistinguishable between those given perioperative anti-inflammatories and those not. One signal did emerge, and it was drug-specific rather than class-wide: after rotator cuff repair, celecoxib was associated with a substantially higher retear rate than ibuprofen. The reviewers were explicit that the body of evidence is too thin to settle the question.
Two practical conclusions follow. Around a tendon-to-bone repair the caution is worth observing, particularly for selective COX-2 inhibitors. As a universal instruction it is not supported, and it has a real cost: pain that goes untreated produces avoidance, and avoidance removes the loading signal the remodeling tissue depends on. What changes around a procedure specifically is a narrower question, answered in Why rest, ice and ibuprofen can sabotage recovery after a regenerative procedure.
The three checkpoints
- Week six. Are pain and function both moving? Pain improving while function stays flat means something is being avoided rather than restored.
- Month three. A stalled repair declares itself here, and the terrain work started at visit one has had a quarter to move what it can move. This is the earliest point at which a catalyst is usually the right conversation.
- Month six to twelve. Whatever the tissue will do unaided, it has largely done. The question shifts from restarting repair to managing a joint's long-term trajectory, which is a different problem.
Frequently Asked Questions
Can I have a regenerative injection in the first few weeks after an injury?
Almost never, and the reason is biological rather than administrative: the repair cascade is already running at full volume, the site is already saturated with platelets, and there is nothing stalled for a catalyst to restart. What a catalyst is actually for is described in Orthobiologics: repairing the system instead of silencing the alarm.
Should I stop anti-inflammatory medication after an injury?
Not on a blanket rule, because the clinical review that looked at this found no significant effect on most soft-tissue repairs and one specific signal around rotator cuff repair, and concluded the data are insufficient to be definitive. What is better established is what happens around a procedure, which is covered in Why rest, ice and ibuprofen can sabotage recovery after a regenerative procedure.
What can actually be changed in twelve weeks?
Glycemic control, inflammatory markers, vitamin D status, sleep architecture and nicotine exposure all move meaningfully inside a quarter, which is why the window is treated as working time rather than waiting time. The panel and what each marker is for is in The Metabolic Audit.
If I do nothing for three months, have I lost the window?
You have lost some ceiling rather than the whole opportunity, because provisional matrix consolidates in the configuration the limb is held in and that part does not come back. Late presentations remain treatable, on the timelines set out in Realistic recovery timelines after orthobiologic treatment.
Why does my pain improve while my function does not?
Because pain settles before capacity returns, and a limb that has stopped hurting is not the same as a limb that has been restored — which is exactly the gap that later becomes a re-injury. Rebuilding capacity rather than comfort is the subject of why load is the treatment.
Find out what your recovery is actually limited by
Regen.MD begins with a physician-led Clinical Evaluation — a review of your history, your imaging and your metabolic data, and a written terrain roadmap before any procedure is discussed. Evaluation is contingent upon review of your data.
Questions? Call (314) 295-3000 or text (314) 886-5902.
Sources
- Constantinescu DS, Campbell MP, Moatshe G, Vap AR. Effects of perioperative nonsteroidal anti-inflammatory drug administration on soft tissue healing: a systematic review of clinical outcomes after sports medicine orthopaedic surgery procedures. Orthop J Sports Med, 2019. PubMed 31019986 doi:10.1177/2325967119838873
- Manchikanti L, Navani R, Navani A, et al. Comprehensive evidence-based guidelines for regenerative therapies in the management of chronic low back pain: 2025 update from the American Society of Interventional Pain Physicians (ASIPP). Pain Physician, 2025. PubMed 41481869
- Kon E, Di Matteo B, Delgado D, et al. Platelet-rich plasma injections for the management of knee osteoarthritis: the ESSKA-ICRS consensus. Recommendations using the RAND/UCLA appropriateness method for different clinical scenarios. Knee Surg Sports Traumatol Arthrosc, 2024. PubMed 38961773 doi:10.1002/ksa.12320
- D'Souza RS, Her YF, Hussain N, et al. Evidence-based clinical practice guidelines on regenerative medicine treatment for chronic pain: a consensus report from a multispecialty working group. J Pain Res, 2024. PubMed 39282657 doi:10.2147/JPR.S480559
- Leong HT, Fu SC, He X, et al. Risk factors for rotator cuff tendinopathy: a systematic review and meta-analysis. J Rehabil Med, 2019. PubMed 31489438 doi:10.2340/16501977-2598
- Laver L, Filardo G, Sanchez M, et al. The use of injectable orthobiologics for knee osteoarthritis: a European ESSKA-ORBIT consensus. Part 1 — blood-derived products (platelet-rich plasma). Knee Surg Sports Traumatol Arthrosc, 2024. PubMed 38436492 doi:10.1002/ksa.12077
- Stone AV, Abed V, Owens M, et al. Randomized controlled trials on platelet-rich plasma for knee osteoarthritis poorly adhere to the Minimum Information for Studies Evaluating Biologics in Orthopaedics (MIBO) guidelines: a systematic review. Am J Sports Med, 2024. PubMed 38282598 doi:10.1177/03635465231185289